ROROTV<- 바로가기 CAMBRIDGE, MASS. & OSAKA, JAPAN--( / ) May 01, 2017 -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that ALUNBRIG™ (brigatinib) has received Accelerated Approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under Accelerated Approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ALUNBRIG, which previously received Breakthrough Therapy Designation from the FDA, is a once-daily oral therapy that may be taken with or without food.
“In recent years, small molecule ALK inhibitors have revolutionized the treatment options for those with advanced ALK+ non-small cell lung cancer. Nevertheless, there is still a need for additional ALK inhibitors like brigatinib (ALUNBRIG), which have a manageable safety profile and may address mechanisms of clinical resistance to crizotinib, including progression in the central nervous system,” said D. Ross Camidge, M.D., Ph.D., director of thoracic oncology at the University of Colorado. “The ALTA trial showed that brigatinib (ALUNBRIG) was highly effective post-crizotinib with the majority of patients who received 180 mg once daily with a seven-day lead in at 90 mg once daily achieving an overall response and a median duration of response greater than one year. Importantly, the extent of activity among those with brain metastases was also notable.”
“For patients with ALK+ metastatic NSCLC who have progressed on or are intolerant to crizotinib, who are facing the uncertainty of disease progression and the potentially devastating impact of brain metastases, the approval of ALUNBRIG offers a new hope,” said Bonnie Addario, founder and chair of the Addario Lung Cancer Foundation (ALCF).
“The rapid development of ALUNBRIG is a tribute to the dedication of many research scientists and clinicians who carefully designed and developed this new medicine to address unmet medical needs in the ALK+ NSCLC patient population. Most importantly, we would like to thank the patients and families who participated in the clinical trials,” said Andy Plump, M.D., Ph.D., Takeda Chief Medical and Scientific Officer.
“Today’s FDA approval of ALUNBRIG is an important milestone in the treatment of patients with ALK+ metastatic NSCLC who have progressed on or are intolerant to crizotinib,” said Christophe Bianchi, M.D., President, Takeda Oncology. “Takeda is committed to the continued development of ALUNBRIG around the globe and to bringing this important therapy to more patients in need.”
About the ALTA Trial
The FDA approval of ALUNBRIG was primarily based on results from the pivotal Phase 2 ALTA (ALK in Lung Cancer Trial of AP26113) trial of brigatinib in adults. This ongoing, two-arm, open-label, multicenter trial enrolled 222 patients with locally advanced or metastatic ALK+ NSCLC who had progressed on crizotinib. Patients received either 90 mg of ALUNBRIG once daily (n=112) or 180 mg once daily following a seven-day lead-in of 90 mg once daily (n=110). The major efficacy outcome measure was confirmed overall response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) as evaluated by an Independent Review Committee (IRC). Additional efficacy outcome measures included Investigator-assessed ORR, duration of response (DOR), intracranial ORR, and intracranial DOR.
The recommended dosing regimen for ALUNBRIG is 90 mg orally once daily for the first 7 days. If 90 mg is tolerated during the first 7 days, increase the dose to 180 mg orally once daily.
With a median follow-up of 8 months (range 0.1 - 20.2), results demonstrated that of the patients who received the recommended dosing regimen (90→180 mg), 53 percent achieved a confirmed overall response (OR) as assessed by IRC and 54 percent as assessed by Investigator. At the recommended dosing regimen, the median duration of response was 13.8 months as assessed by IRC and 11.1 months by Investigator assessment. Additionally, at the recommended dosing regimen, 67 percent of patients with measurable brain metastases (n=18) achieved a confirmed intracranial OR by IRC assessment.
Efficacy data are as follows: (To view the tables, please visit )
Among the 23 patients who exhibited an intracranial response, 78% of patients in the 90 mg arm and 68% of patients in the 90→180 mg group maintained a response for at least four months.
The warnings and precautions for ALUNBRIG are: interstitial lung disease (ILD)/pneumonitis, hypertension, bradycardia, visual disturbance, creatine phosphokinase (CPK) elevation, pancreatic enzyme elevation, hyperglycemia and embryo-fetal toxicity.
Serious adverse reactions occurred in 38% of patients in the 90 mg group and 40% of patients in the 90→180 mg group. The most common serious adverse reactions were pneumonia (5.5% overall, 3.7% in the 90 mg group, and 7.3% in the 90→180 mg group) and ILD/pneumonitis (4.6% overall, 1.8% in the 90 mg group and 7.3% in the 90→180 mg group). Fatal adverse reactions occurred in 3.7% of patients and consisted of pneumonia (2 patients), sudden death, dyspnea, respiratory failure, pulmonary embolism, bacterial meningitis and urosepsis (1 patient each).
At the recommended dosing regimen, the most common adverse reactions (≥25%) with ALUNBRIG were nausea, diarrhea, fatigue, cough, and headache.
About ALK+ NSCLC
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 85 percent of the estimated 222,500 new cases of lung cancer diagnosed each year in the United States, according to the American Cancer Society. Genetic studies indicate that chromosomal rearrangements in anaplastic lymphoma kinase (ALK) are key drivers in a subset of NSCLC patients as well. Approximately two to eight percent of patients with NSCLC have a rearrangement in the ALK gene.
The central nervous system (CNS) is a frequent site for ALK+ NSCLC progression, with up to 70 percent of patients with ALK+ NSCLC who have been treated with a first-line ALK inhibitor facing brain metastases.
About ALUNBRIG™ (brigatinib)
ALUNBRIG is a targeted cancer medicine discovered by ARIAD Pharmaceuticals, Inc., which was acquired by Takeda in February 2017. ALUNBRIG received Breakthrough Therapy Designation from the FDA for the treatment of patients with ALK+ NSCLC whose tumors are resistant to crizotinib, and was granted Orphan Drug Designation by the FDA for the treatment of ALK+ NSCLC, ROS1+ and EGFR+ NSCLC. A Marketing Authorization Application (MAA) for ALUNBRIG was submitted to the European Medicines Agency (EMA) in February 2017.
The ALTA clinical development program further reinforces Takeda’s ongoing commitment to developing innovative therapies for people living with ALK+ NSCLC worldwide and the healthcare professionals who treat them. In addition to the ongoing Phase 1/2 and Phase 2 ALTA trial, brigatinib is also being studied in the Phase 3 ALTA 1L trial to assess its efficacy and safety in comparison to crizotinib in patients with locally advanced or metastatic ALK+ NSCLC who have not received prior treatment with an ALK inhibitor.
To learn more about ALUNBRIG, please visit or call A1Point: 1-844-A1POINT (1-844-217-6468).
For additional information on the brigatinib clinical trials, please visit
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with ALUNBRIG. In Trial ALTA (ALTA), ILD/pneumonitis occurred in 3.7% of patients in the 90 mg group (90 mg once daily) and 9.1% of patients in the 90→180 mg group (180 mg once daily with 7-day lead-in at 90 mg once daily). Adverse reactions consistent with possible ILD/pneumonitis occurred early (within 9 days of initiation of ALUNBRIG; median onset was 2 days) in 6.4% of patients, with Grade 3 to 4 reactions occurring in 2.7%. Monitor for new or worsening respiratory symptoms (e.g., dyspnea, cough, etc.), particularly during the first week of initiating ALUNBRIG. Withhold ALUNBRIG in any patient with new or worsening respiratory symptoms, and promptly evaluate for ILD/pneumonitis or other causes of respiratory symptoms (e.g., pulmonary embolism, tumor progression, and infectious pneumonia). For Grade 1 or 2 ILD/pneumonitis, either resume ALUNBRIG with dose reduction after recovery to baseline or permanently discontinue ALUNBRIG. Permanently discontinue ALUNBRIG for Grade 3 or 4 ILD/pneumonitis or recurrence of Grade 1 or 2 ILD/pneumonitis.
Hypertension: In ALTA, hypertension was reported in 11% of patients in the 90 mg group who received ALUNBRIG and 21% of patients in the 90→180 mg group. Grade 3 hypertension occurred in 5.9% of patients overall. Control blood pressure prior to treatment with ALUNBRIG. Monitor blood pressure after 2 weeks and at least monthly thereafter during treatment with ALUNBRIG. Withhold ALUNBRIG for Grade 3 hypertension despite optimal antihypertensive therapy. Upon resolution or improvement to Grade 1 severity, resume ALUNBRIG at a reduced dose. Consider permanent discontinuation of treatment with ALUNBRIG for Grade 4 hypertension or recurrence of Grade 3 hypertension. Use caution when administering ALUNBRIG in combination with antihypertensive agents that cause bradycardia.
Bradycardia: Bradycardia can occur with ALUNBRIG. In ALTA, heart rates less than 50 beats per minute (bpm) occurred in 5.7% of patients in the 90 mg group and 7.6% of patients in the 90→180 mg group. Grade 2 bradycardia occurred in 1 (0.9%) patient in the 90 mg group. Monitor heart rate and blood pressure during treatment with ALUNBRIG. Monitor patients more frequently if concomitant use of drug known to cause bradycardia cannot be avoided. For symptomatic bradycardia, withhold ALUNBRIG and review concomitant medications for those known to cause bradycardia. If a concomitant medication known to cause bradycardia is identified and discontinued or dose adjusted, resume ALUNBRIG at the same dose following resolution of symptomatic bradycardia; otherwise, reduce the dose of ALUNBRIG following resolution of symptomatic bradycardia. Discontinue ALUNBRIG for life-threatening bradycardia if no contributing concomitant medication is identified.
Visual Disturbance: In ALTA, adverse reactions leading to visual disturbance including blurred vision, diplopia, and reduced visual acuity, were reported in 7.3% of patients treated with ALUNBRIG in the 90 mg group and 10% of patients in the 90→180 mg group. Grade 3 macular edema and cataract occurred in one patient each in the 90→180 mg group. Advise patients to report any visual symptoms. Withhold ALUNBRIG and obtain an ophthalmologic evaluation in patients with new or worsening visual symptoms of Grade 2 or greater severity. Upon recovery of Grade 2 or Grade 3 visual disturbances to Grade 1 severity or baseline, resume ALUNBRIG at a reduced dose. Permanently discontinue treatment with ALUNBRIG for Grade 4 visual disturbances.
Creatine Phosphokinase (CPK) Elevation: In ALTA, creatine phosphokinase (CPK) elevation occurred in 27% of patients receiving ALUNBRIG in the 90 mg group and 48% of patients in the 90 mg→180 mg group. The incidence of Grade 3-4 CPK elevation was 2.8% in the 90 mg group and 12% in the 90→180 mg group. Dose reduction for CPK elevation occurred in 1.8% of patients in the 90 mg group and 4.5% in the 90→180 mg group. Advise patients to report any unexplained muscle pain, tenderness, or weakness. Monitor CPK levels during ALUNBRIG treatment. Withhold ALUNBRIG for Grade 3 or 4 CPK elevation. Upon resolution or recovery to Grade 1 or baseline, resume ALUNBRIG at the same dose or at a reduced dose.
Pancreatic Enzyme Elevation: In ALTA, amylase elevation occurred in 27% of patients in the 90 mg group and 39% of patients in the 90→180 mg group. Lipase elevations occurred in 21% of patients in the 90 mg group and 45% of patients in the 90→180 mg group. Grade 3 or 4 amylase elevation occurred in 3.7% of patients in the 90 mg group and 2.7% of patients in the 90→180 mg group. Grade 3 or 4 lipase elevation occurred in 4.6% of patients in the 90 mg group and 5.5% of patients in the 90→180 mg group. Monitor lipase and amylase during treatment with ALUNBRIG. Withhold ALUNBRIG for Grade 3 or 4 pancreatic enzyme elevation. Upon resolution or recovery to Grade 1 or baseline, resume ALUNBRIG at the same dose or at a reduced dose.
Hyperglycemia: In ALTA, 43% of patients who received ALUNBRIG experienced new or worsening hyperglycemia. Grade 3 hyperglycemia, based on laboratory assessment of serum fasting glucose levels, occurred in 3.7% of patients. Two of 20 (10%) patients with diabetes or glucose intolerance at baseline required initiation of insulin while receiving ALUNBRIG. Assess fasting serum glucose prior to initiation of ALUNBRIG and monitor periodically thereafter. Initiate or optimize anti-hyperglycemic medications as needed. If adequate hyperglycemic control cannot be achieved with optimal medical management, withhold ALUNBRIG until adequate hyperglycemic control is achieved and consider reducing the dose of ALUNBRIG or permanently discontinuing ALUNBRIG.
Embryo-Fetal Toxicity: Based on its mechanism of action and findings in animals, ALUNBRIG can cause fetal harm when administered to pregnant women. There are no clinical data on the use of ALUNBRIG in pregnant women. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with ALUNBRIG and for at least 4 months following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for at least 3 months after the last dose of ALUNBRIG.
ADVERSE REACTIONS
Serious adverse reactions occurred in 38% of patients in the 90 mg group and 40% of patients in the 90→180 mg group. The most common serious adverse reactions were pneumonia (5.5% overall, 3.7% in the 90 mg group, and 7.3% in the 90→180 mg group) and ILD/pneumonitis (4.6% overall, 1.8% in the 90 mg group and 7.3% in the 90→180 mg group). Fatal adverse reactions occurred in 3.7% of patients and consisted of pneumonia (2 patients), sudden death, dyspnea, respiratory failure, pulmonary embolism, bacterial meningitis and urosepsis (1 patient each).
The most common adverse reactions (≥25%) in the 90 mg group were nausea (33%), fatigue (29%), headache (28%), and dyspnea (27%) and in the 90→180 mg group were nausea (40%), diarrhea (38%), fatigue (36%), cough (34%), and headache (27%).
DRUG INTERACTIONS
CYP3A Inhibitors: Avoid concomitant use of ALUNBRIG with strong CYP3A inhibitors. Avoid grapefruit or grapefruit juice as it may also increase plasma concentrations of brigatinib. If concomitant use of a strong CYP3A inhibitor is unavoidable, reduce the dose of ALUNBRIG.
CYP3A Inducers: Avoid concomitant use of ALUNBRIG with strong CYP3A inducers.
CYP3A Substrates: Coadministration of ALUNBRIG with CYP3A substrates, including hormonal contraceptives, can result in decreased concentrations and loss of efficacy of CYP3A substrates.
USE IN SPECIFIC POPULATIONS
Pregnancy: ALUNBRIG can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus.
Lactation: Advise lactating women not to breastfeed during treatment with ALUNBRIG and for 1 week following the final dose.
Females and Males of Reproductive Potential:
Contraception: Advise females of reproductive potential to use effective non-hormonal contraception during treatment with ALUNBRIG and for at least 4 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with ALUNBRIG and for at least 3 months after the final dose.
Infertility: ALUNBRIG may cause reduced fertility in males.
Pediatric Use: The safety and efficacy of ALUNBRIG in pediatric patients have not been established.
Geriatric Use: Clinical studies of ALUNBRIG did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. Of the 222 patients in ALTA, 19.4% were 65-74 years and 4.1% were 75 years or older. No clinically relevant differences in safety or efficacy were observed between patients ≥65 and younger patients.
Hepatic or Renal Impairment: No dose adjustment is recommended for patients with mild hepatic impairment or mild or moderate renal impairment. The safety of ALUNBRIG in patients with moderate or severe hepatic impairment or severe renal impairment has not been studied.
Please see the full Prescribing Information for ALUNBRIG at
About Takeda
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit
Additional information about Takeda is available through its corporate website, , and additional information about Takeda Oncology, the brand for the global oncology business unit of Takeda Pharmaceutical Company Limited, is available through its website,
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
AUSTIN, TEXAS--( / ) January 06, 2020 -- High performance, low power Universal Flash Storage (UFS) represents the future of mobile storage, as underscored by the wide adoption of embedded mobile 누드모델 탑파일 products, and the recent arrival of removable UFS Cards. With 2019 launches of some UFS Card systems underway, 누드모델 2020 is expected to be the year that UFS Cards become the industry choice for removable mobile storage.
September 2019: UFS Card ROROTV won best product 누드모델 듀얼플리커 innovation award at CFMS (China Flash Market Summit) in 누드모델 세이프토토 SeptemberChina
Sequential 누드모델 플리커현상 정사 Sequentialperformance ROROTV 외국사진사이트 5x faster than SD card
Random 누드모델 jesuya Read 누드모델 performance 70x ROROTV 소셜네트워크 faster than SD card
UFS is a superior open-standard flash memory interface ROROTV 전효성허리돌리기 developed by JEDEC (world leader in semiconductor standards), first used 누드모델 허리돌리기운동 in embedded storage 누드모델 and extended to UFS Card storage using a royalty-free form factor. Higher performance versions of UFS and UFS Cards continue to 누드모델 포토샵추천 be developed, as well.
UFSA (Universal Flash Storage Association) has coordinated 누드모델 김태희 with JEDEC and industry leaders to develop compliance testing and logo certification programs for UFS 알고잡 UFSAcreate a robust ecosystem, enabling system houses to launch 누드모델 자동차추천 UFS Card systems with multiple 누드모델 suppliers.
“Embedded UFS and UFS Cards demonstrate the power of leading-edge companies working together through JEDEC and the UFSA, responding to the global need for higher performance storage, and related open-standard products,” 누드모델 지하철쩍벌녀 said Mian Quddus, Board Chairman for JEDEC and the UFSA.
Through several 누드모델 스타골든벨송혜교 compliance 누드모델 여중생 workshops, UFSA ROROTV 소설여고생 has certified multiple UFS Cards as well 누드모델 고딩치마 as several UFS controllers and controller IP. Coupled with multiple socket suppliers and UFS-to-USB bridge chips, the new UFS suppliers have fortified the UFS ecosystem now in place for system 야한망가 Through
“UFSA created the compliance testing environment for the JEDEC ROROTV UFS standard 누드모델 인천연예인 to enable high confidence in certified products,” said Perry Keller, Keysight Digital Standards and Applications Program lead, and UFSA Compliance Chairman. “UFSA continues to hold workshops to permit certification of additional products and suppliers.”
Test equipment products from Keysight, BitifEye, and Protocol Insight have been instrumental 성인엽기 Testexpanding 누드모델 the environment for enabling automated 누드모델 바카라노하우 testing and certification.
A proliferation of embedded UFS products has occurred rapidly for a wide range of applications including smartphones, tablets and drones. The ramp of UFS Cards, however, because it directly involves the end user, requires extensive compliance and compatibility testing to insure interoperability among suppliers. Since UFSA created its compliance test matrix, it has certified a robust set of suppliers. Recent introductions by LG and Samsung Electronics add 누드모델 레터링가격 to the growing list of laptops and Netbook computers supporting UFS Cards. (links 스피드 Abelow)
Three 누드모델 신헤어라인 UFS Card developers have UFSA-certified devices (Phison, Samsung Electronics, and Silicon ROROTV 상업정보 서윤 Three누드모델 놀이터추천 (SMI)).
“We are ready to 누드모델 부산여자 support the industry as the market accelerates,” said Horace 서윤 “WeDirector of 누드모델 바카라게임 Mobile Storage at Phison and UFSA Board member.
“UFS Cards will play a critical role in speeding 누드모델 성남아이롱다운펌 up the storage process, and growing storage capacity,” said Hangu Sohn, vice president of NAND Memory Planning at 누드모델 인천아이롱다운펌 Samsung Electronics. 서윤 “UFSwith a royalty-free form factor and open standard design, we expect to 누드모델 baccarat see a rapid transition to these cards in 2020.”
“We are active contributors 누드모델 안양미용실 to UFS controller and Card designs and we are ready to meet ROROTV 카드게임 the needs of the industry as it ramps up,” said Robert Hsieh, Director of Mobile Storage Marketing at Silicon Motion and UFSA Board member.
Adding the capabilities of USB3.1 and USB Type C card 누드모델 광주미용실추천 readers for UFS enables the 누드모델 광주매직 UFS Card to be the transfer device of choice between devices. (link below)
At the recent IFA Berlin, the Hisense T91 cell phone prototype demonstrated UFS Cards run circles around microSD cards with 6x faster sequential read and write speeds, and 35x better random writes. The UFS Card is also a good deal faster 엠스팟 Atbuilt-in 누드모델 eMMC storage that is commonly used in non-premium devices. The numbers come close to the speed of built-in UFS 2.1, which was used in recent flagships (e.g. Galaxy S10, Huawei P30 and others). Clearly the UFS Card technology is ready and ROROTV 태양성카지노 Qualcomm’s chipsets support it.
UFS 누드모델 네임드 eco ROROTV 프로토 system providers 누드모델 바카라 within 알바페어 UFS누드모델 네임드사다리
· 누드모델 카지노바카라게임 Certified 누드모델 Golden 누드모델 프로토승부식 UFS Cards - Phison, Samsung Electronics, SMI ROROTV
· Certified UFS 누드모델 네임드사다리게임 오카이69 ·누드모델 - ROROTV 블랙잭잘하는법 Phison, SMI
· Certified Controller IP - ROROTV 아시안카지노 Synopsys 누드모델 코리아카지노
2013야마토 ·UFS to USB Bridge 누드모델 섯다족보 Controllers - SMI, ROROTV 강원랜드칩걸 JMicron
· 누드모델 Sockets - 누드모델 메가888::카지노 Amphenol, Molex
· Test Equipment - BitifEye, 누드모델 해외배당 Keysight, Protocol Insight
· Test 누드모델 다모아바카라 Fixtures 누드모델 다모아카지노 - Astek
Related 누드모델 비비카지노 ROROTV 비비카지노 마징가TV Related누드모델 타짜카지노
About UFSA 누드모델 크라운카지노 ROROTV 크라운카지노
The Universal Flash 누드모델 소라카지노 Storage Association (UFSA) 마징가TV Thean open Trade Association created to support the widespread 누드모델 신정환카지노 adoption and acceptance of the JEDEC UFS standard. UFSA’s primary mission includes the promotion of UFS technology and infrastructure by 누드모델 바둑이사이트 providing product compliance and UFS logo certification management. Through compliance testing UFSA provides valuable input back to JEDEC for future specification development.
About 누드모델 카지노빠 JEDEC 누드모델 정선바카라
JEDEC is the global leader in the development 누드모델 온라인바카라주소 of standards for 누드모델 고카지노 the microelectronics industry. Thousands of volunteers representing nearly 300 member companies work together in over 100 JEDEC technical committees and task groups to meet the needs of every segment of the industry, manufacturers and consumers alike. The publications and standards generated by JEDEC committees are accepted throughout the world. All JEDEC standards are available for download from the JEDEC 마징가TV JEDECFor ROROTV more information, visit
섹녀 Forward-Looking누드모델 룰렛 ROROTV 룰렛 Statements 누드모델 헬로카지노주소
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding the expected release and benefits of UFS. Any statements that are not statements of historical fact may be deemed to be forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that could cause actual results, time frames or achievements to differ materially from those expressed or implied in 누드모델 해외카지노 the forward-looking statements. UFSA undertakes no obligation to update publicly any forward-looking statements, or to update the 누드모델 reasons actual results could differ materially from those 누드모델 로또 anticipated in these forward-looking statements, even if new information becomes available in the future.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s 누드모델 포커 largest 누드모델 경마예상 press release distribution network
